Every material Form 8-K Cytek Biosciences, Inc. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cytek Biosciences reported third-quarter 2026 revenue of $53.2 million, up 2% from a year earlier, and a GAAP gross margin of 59%, up from 53%. The net loss widened to $6.1 million from $5.5 million, and the company kept the midpoint of its full-year 2026 revenue guidance while narrowing the range to $208 million to $211 million.
Q3 2026 total revenue was $53.2 million, a 2% increase; U.S. revenue grew 12%.
Q3 2026 net loss was $6.1 million, compared with $5.5 million in Q3 2025; adjusted EBITDA was $0.7 million versus $2.5 million.
Full-year 2026 revenue guidance midpoint maintained; range narrowed to $208 million to $211 million.
Cash, cash equivalents, restricted cash and marketable securities were $256.3 million at September 30, 2026, down $5.7 million from June 30, 2026.
On August 21, 2026, a Delaware federal jury returned a verdict in patent infringement action brought by Beckman Coulter against Cytek Biosciences. The jury found noninfringement and invalidity on three of four asserted claims, but found infringement under the doctrine of equivalents on one claim and awarded $20 million in lost profits and $36.11 million in royalties. The company plans post-verdict motions and may appeal, and says the verdict does not require changes to its current products or operations.
Jury found noninfringement and invalidity on three of the four asserted patent claims.
On the remaining claim, jury found no literal infringement but found infringement under the doctrine of equivalents.
Past damages awarded: $20 million in lost profits and $36.11 million in royalties.
Company intends to pursue post-verdict motions and may appeal to the Federal Circuit; it says its products remain available.
Cytek Biosciences reported second-quarter 2026 revenue of $48.1 million, up 6% from a year earlier, and raised the midpoint of its full-year 2026 revenue guidance by $1 million. Net loss widened to $12.2 million from $5.6 million, driven by higher operating expenses, including a 24% rise in general and administrative expenses tied to litigation, severance and personnel costs.
Q2 2026 total revenue $48.1 million, up 6% from Q2 2025; gross profit $28.3 million, up 19%
Net loss $12.2 million in Q2 2026 versus $5.6 million in Q2 2025; operating expenses rose 15% to $39.7 million
Full-year 2026 total revenue guidance updated to $207 million to $212 million, midpoint raised by $1 million
Cash, cash equivalents and marketable securities totaled $262.0 million as of June 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cytek Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →